Danny Nguyen, MD

Articles by Danny Nguyen, MD

Next Steps for Investigation of Mobocertinib for EGFR Exon 20+ NSCLC

April 14th 2022

Danny Nguyen, MD, discusses next steps for research of mobocertinib in patients with EGFR-positive non–small cell lung cancer.

Efficacy of Mobocertinib Lowered by Dose Reductions in EGFR+ NSCLC

ByDanny Nguyen, MD

January 18th 2022

Danny Nguyen, MD, discusses an analysis of efficacy and adverse events of mobocertinib in patients with EGFR-positive non–small cell lung cancer that was presented at the European Society for Medical Oncology 2021 Congress.

Danny Nguyen, MD

Articles by Danny Nguyen, MD

Next Steps for Investigation of Mobocertinib for EGFR Exon 20+ NSCLC

Efficacy of Mobocertinib Lowered by Dose Reductions in EGFR+ NSCLC

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma